$Kodiak Sciences (KOD.US)$ announced first time results of K...
$Kodiak Sciences(KOD.US$ announced first time results of KSI-501 ABC Phase 1 study. The data outlined safety and biocativity of KSI-501, along with high binding affinity and bioactivity against VEGF and IL-6.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment